Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition
NCT06010719Phase 4Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Oct 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of azithromycin in severe acute malnutrition (SAM) (3 arms), sponsored by University of California, San Francisco. Primary endpoint: Weight Gain at 8 weeks. Started Oct 2024; status: recruiting.
02
Drugs
azithromycin
03
Conditions
severe acute malnutrition (SAM)
Beyond the preview
Go deeper on NCT06010719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010719.